Evidence map›Paper›PMID 27533307›Full record

Trial reportThe Journal of clinical endocrinology and metabolism2016

Changes in Weight and Glucose Can Protect Against Progression in Early Diabetes Independent of Improvements in β-Cell Function.

Y R Patel, M S Kirkman, R V Considine, T S Hannon, K J Mather

Abstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in The Journal of clinical endocrinology and metabolism, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Weight Change, Lifestyle, and Mortality in Patients With Type 2 Diabetes.The Journal of clinical endocrinology and metabolism · 2022
    Observational
  3. The linearized disposition index augments understanding of treatment effects in diabetes.American journal of physiology. Endocrinology and metabolism · 2021
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Y R PatelIndiana University School of Medicine (Y.R.P., M.S.K., R.V.C., T.S.H., K.J.M.), Indianapolis, Indiana 46202; Harvard University (Y.R.P.), Cambridge, Massachusetts 02138; and University of North Carolina (M.S.K.), Chapel Hill, North Carolina 27599.
M S KirkmanIndiana University School of Medicine (Y.R.P., M.S.K., R.V.C., T.S.H., K.J.M.), Indianapolis, Indiana 46202; Harvard University (Y.R.P.), Cambridge, Massachusetts 02138; and University of North Carolina (M.S.K.), Chapel Hill, North Carolina 27599.
R V ConsidineIndiana University School of Medicine (Y.R.P., M.S.K., R.V.C., T.S.H., K.J.M.), Indianapolis, Indiana 46202; Harvard University (Y.R.P.), Cambridge, Massachusetts 02138; and University of North Carolina (M.S.K.), Chapel Hill, North Carolina 27599.
T S HannonIndiana University School of Medicine (Y.R.P., M.S.K., R.V.C., T.S.H., K.J.M.), Indianapolis, Indiana 46202; Harvard University (Y.R.P.), Cambridge, Massachusetts 02138; and University of North Carolina (M.S.K.), Chapel Hill, North Carolina 27599.
K J MatherIndiana University School of Medicine (Y.R.P., M.S.K., R.V.C., T.S.H., K.J.M.), Indianapolis, Indiana 46202; Harvard University (Y.R.P.), Cambridge, Massachusetts 02138; and University of North Carolina (M.S.K.), Chapel Hill, North Carolina 27599.

Funding

WU P&FP30DK020579 · NIDDK · WASHINGTON UNIVERSITY · PI Clay F. Semenkovich · 2013 to 2026
$27.1M
ZOSUQUIDAR TRIHYDROCHLORIDE DURING CONVENTIONAL INDUCTION AND POST-REMISSIONM01RR000750 · NCRR · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI STORNIOLO, ANNA · 1985 to 2008
$25.5M
YOGA FOR THE MANAGEMENT OF HIV-METABOLIC SYNDROMESM01RR000036 · NCRR · WASHINGTON UNIVERSITY · PI REEDS, DOMINIC N · 1985 to 2007
$25.4M
TRANSGENICS COREP60DK020579 · NIDDK · WASHINGTON UNIVERSITY · PI SCHAFFER, JEAN E. · 1986 to 2012
$25.2M
Translation CoreP30DK097512 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI Carmella Evans-Molina · 2015 to 2026
$17.4M
NCRR NIH HHS M01 RR000036NCRR NIH HHS M01 RR000750NIDDK NIH HHS P30 DK020579NIDDK NIH HHS P30 DK097512NIDDK NIH HHS P60 DK020579
6 · The paper itself

Abstract

contextEvidence-based strategies to prevent progression of dysglycemia in newly diagnosed type 2 diabetes are needed.

objectiveTo undertake a secondary analysis of the Early Diabetes Intervention Program (EDIP) in order to understand the features that were protective against worsening glycemia.

designEDIP was a randomized, placebo-controlled trial.

settingTwo university diabetes centers. PATIENTS: A total of 219 overweight individuals with fasting glucose < 7.8 mmol/L and 2-hour oral glucose tolerance test (OGTT) glucose > 11.1 mmol/L.

interventionsAcarbose versus placebo, on a background of dietary recommendations, with quarterly visits to assess glycemia and intervention adherence for up to 5 years.

main outcome measuresProgression of fasting glucose ≥ 7.8 mmol/L on two consecutive quarterly visits. Cox proportional hazards modeling and ANOVA were performed to evaluate determinants of progression.

resultsProgression-free status was associated with reductions in weight, fasting glucose, 2-hour OGTT glucose, and increases in the high-density lipoprotein/triglyceride ratio. The reduction in fasting glucose was the only effect that remained significantly associated with progression-free status in multivariable Cox modeling. The reduction in fasting glucose was in turn primarily associated with reductions in weight and in 2-hour OGTT glucose. Acarbose treatment did not explain these changes.

conclusionsIn early diabetes, reductions in glucose, driven by reductions in weight, can delay progressive metabolic worsening. These observations underscore the importance of lifestyle management including weight loss as a tool to mitigate worsening of glycemia in newly diagnosed diabetes.

Indexed as

Disease ProgressionOutcome Assessment, Health CareWeight LossAcarboseAdultAgedBlood GlucoseCombined Modality TherapyDiabetes Mellitus, Type 2Diet, Carbohydrate-RestrictedDiet, ReducingFemaleGlycoside Hydrolase InhibitorsHumansInsulin-Secreting CellsMaleAcarboseBlood GlucoseGlycoside Hydrolase Inhibitors

Identifiers

PMID27533307
PMCPMC5095260

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.